Quantum BioPharma Ltd.
QNTM
$18.09
$0.0350.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.69% | 3.17% | -25.69% | -35.32% | -40.51% |
| Depreciation & Amortization | -4.03% | -66.58% | -80.43% | -85.89% | -88.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.31% | 42.47% | -16.10% | -52.89% | -62.54% |
| Operating Income | -76.31% | -42.47% | 16.10% | 52.89% | 62.54% |
| Income Before Tax | -240.09% | -108.06% | 18.18% | 51.11% | 71.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -240.09% | -108.06% | 18.18% | 51.11% | 71.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 26.89% | 33.20% | 117.08% | 1,123.95% | -- |
| Net Income | -261.70% | -111.98% | 20.66% | 54.82% | 74.00% |
| EBIT | -76.31% | -42.47% | 16.10% | 52.89% | 62.54% |
| EBITDA | -80.52% | -57.83% | 6.47% | 47.28% | 57.59% |
| EPS Basic | -11.37% | 6.65% | 50.12% | 61.89% | 75.07% |
| Normalized Basic EPS | 3.67% | 9.53% | 50.28% | 66.04% | 69.25% |
| EPS Diluted | -11.37% | 6.68% | 50.61% | 62.19% | 75.34% |
| Normalized Diluted EPS | 3.67% | 9.53% | 50.28% | 66.04% | 69.25% |
| Average Basic Shares Outstanding | 241.31% | 148.36% | 72.12% | 15.86% | 3.37% |
| Average Diluted Shares Outstanding | 241.31% | 148.36% | 72.12% | 15.86% | 3.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |